Stay updated on Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The page footer revision tag was updated from **v3.5.2** to **v3.5.3**, indicating a site/platform version update rather than a change to the study information.
    Difference
    0.0%
    Check dated 2026-04-24T22:24:17.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    Added related topics: Lung cancer and MedlinePlus Genetics. Updated the page revision from v3.5.0 to v3.5.2.
    Difference
    0.2%
    Check dated 2026-04-17T14:13:13.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    Removed the Lung cancer topic and the MedlinePlus Genetics related topic from the study's topics section. This may reduce discoverability for NSCLC-related searches and related genetic resources.
    Difference
    0.1%
    Check dated 2026-04-10T09:00:25.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    Added related topics to the study page: Lung cancer and MedlinePlus Genetics.
    Difference
    0.1%
    Check dated 2026-04-03T05:39:05.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    The site was updated to Revision: v3.5.0, and Lung cancer, related topics (MedlinePlus Genetics), and Revision: v3.4.3 were removed.
    Difference
    0.2%
    Check dated 2026-03-19T23:42:15.000Z thumbnail image
  8. Check
    59 days ago
    Change Detected
    Summary
    Lung cancer is added as a related topic and a MedlinePlus Genetics link appears under related topics. The site revision is updated to v3.4.3, replacing v3.4.2.
    Difference
    0.2%
    Check dated 2026-03-12T20:41:38.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.